Low expression of Rap1GAP is associated with epithelial-mesenchymal transition (EMT) and poor prognosis in gastric cancer

Ya Yang; Jia Zhang; Yan Yan; Hui Cai; Min Li; Kai Sun; Jizhao Wang; Xu Liu; Jiansheng Wang; Xiaoyi Duan

doi:10.18632/oncotarget.14074

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Low expression of Rap1GAP is associated with epithelial-mesenchymal transition (EMT) and poor prognosis in gastric cancer

Ya Yang _, Jia Zhang, Yan Yan, Hui Cai, Min Li, Kai Sun, Jizhao Wang, Xu Liu, Jiansheng Wang and Xiaoyi Duan

PDF | HTML | How to cite

Oncotarget. 2017; 8:8057-8068. https://doi.org/10.18632/oncotarget.14074

Metrics: PDF 1864 views | HTML 2351 views | ?

Abstract

Ya Yang1,4,*, Jia Zhang1,*, Yan Yan1, Hui Cai2, Min Li1, Kai Sun1, Jizhao Wang1, Xu Liu1, Jiansheng Wang1, Xiaoyi Duan3

1The Second Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China

2Department of Vascular Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China

3Department of Radiology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China

4Department III of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan, China

*These authors have contributed equally to this work

Correspondence to:

Xiaoyi Duan, email: [email protected]

Jiansheng Wang, email: [email protected]

Keywords: gastric cancer, RAP1 GTPase activating protein (Rap1GAP), E-cadherin, Matrix metalloproteinase-2, prognosis

Received: October 19, 2015 Accepted: November 21, 2016 Published: December 21, 2016

ABSTRACT

Rap1GAP is a crucial tumor suppressor, but its role in gastric cancer (GC) is little investigated. In this study, we found that the expression of Rap1GAP was decreased in GC. Low expression of Rap1GAP was positively correlated with advanced pTNM stage, Borrmann types, tumor diameter and poor prognosis in patients with GC. Low expression of Rap1GAP correlated with loss of E-cadherin expression, and anomalous positivity of MMP2 expression. Multivariate analysis showed that low expression of Rap1GAP was an independent prognostic factor. Ectopic expression of Rap1GAP impaired cell migration and invasion, promoted the expression of E-cadherin and decreased the expression of MMP2. These results suggest that Rap1GAP functions as a novel suppressor of EMT and tumor metastasis in GC, and loss of Rap1GAP predicts poor prognosis in GC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14074

Publication Alerts

Research Papers:

Low expression of Rap1GAP is associated with epithelial-mesenchymal transition (EMT) and poor prognosis in gastric cancer

Abstract